1.Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-16740.
2.Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88:2692-2696.
3.Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62:167-215.
4.Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299:125-140.
5.Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib,a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-412.
6.Katori M, Majima M. Cyclooxygenase-2: Its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000; 49:367-392.
7.Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998; 47:S78-87.
8.Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002; 39:521-522.
9.Chen C-S, Tan C-M, Huang C-H, Chang L-C, Wang J-P, Cheng F-C, et al. Discovery of 3-(4-bromophenyl)- 6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-[alpha] production. Bioorg Med Chem 2010; 8:597-604.
10.Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S. Synthesis and biological evaluation of the 1.5 diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40:1347-1365.
11.Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, et al.The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone],an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 1999; 9:1773-1778.
12.Friesen RW, Dube D, Fortin R, Frenette R, Prescott S, Cromlish W, et al. Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2inhibitors. Bioorg Med Chem Lett 1996; 6:2677-2682.
13.Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43:775-777.
14.Zarghi A, Rao PN, Knaus EE. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. J Pharm Pharm Sci 2007; 10:159-167.
15.Isikdag I, Meric A. Syntheses and analgesic activities of some 2-substituted-4,5-diphenyl and 1,2-disubstituted 4.5-diphenyl imidazole derivatives. Boll Chim Farm 1999; 138:24-29.
16.Hadizadeh F, Vosooghi R. Synthesis of a-[5-(5-Amino-1,3,4-thiadiazol-2-yl)-2-imidazolylthio]acetic acids. J Heterocyclic Chem 2008; 45:1477-1479.
17.Morris GM, Doodsell DS, Holliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998; 19:1639-1662.
18.Hosseinzadeh H, Ramezani M, Salmani G. Antinociceptive, anti-inflammatory and acute toxicity effects of Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol 2000; 73:379-385.
19.Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003; 278:45763-45769.
20.Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein- ligand interactions. Protein Eng 1995; 8:127-134.